Dahu Aquaculture responds to regulatory inquiry on semi-annual report

In response to a regulatory inquiry, Dahu Aquaculture provided a detailed breakdown of its 2025 semi-annual performance across key segments: aquatic products, medical services, and liquor. The company reported a total operating revenue of 421.9393 million yuan, a decrease of 13.71% year-on-year, but managed to reduce its net loss attributable to the parent company by 8.9273 million yuan, achieving a profit of 21.8194 million yuan. The aquatic products segment saw a revenue decline of 17.60%, primarily due to the divestiture of its live soft-shelled turtle business and weak market conditions for live fish, although frozen aquatic products experienced an 18.06% revenue increase.

The company's liquor business reported a 17.06% revenue decrease, mainly attributed to intense market competition and strategic adjustments in product offerings. Medical services recorded an 8.36% revenue decrease, but an increase in bed utilization rates and daily fees for some hospitals contributed positively. The decline in medical services profit was attributed to the reversal of deferred income tax assets.

Furthermore, Dahu Aquaculture detailed its inventory, with a book value of 445.5758 million yuan, including biological assets valued at 284.4910 million yuan. The company confirmed that no inventory impairment provisions were made, as the net realizable value of its biological assets exceeded their book value, validated by independent aquatic science experts and consistent inventory valuation methods.